Document is current
Any future updates will be listed below
-
Authors
Ritt, Philipp
Fernández, René
Soza-Ried, Cristian
Nicolai, Heinz
Amaral, Horacio
Krieger, Korbinian
Mapanao, Ana Katrina
Rotger, Amanda
Zhernosekov, Konstantin
Schibli, Roger
Müller, Cristina
Kramer, Vasko
-
Funding
Funding for this research was provided by:
ICPO (ICPO)
ETH MedLab Fellowship (ETH MedLab Fellowship)
SNSF (320030_188978)
Horizon 2020 EU (884104)
- License Information
-
More Information
Article History
Received: 23 September 2024
Accepted: 17 January 2025
First Online: 3 February 2025
Declarations
:
: All procedures performed in this study involving human patients were in accordance with the ethical standards of the institutional and national research committee and with the principles of the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. The study was approved by the regional ethics committee board (CEC SSM Oriente, permit 20210521) and written informed consent has been obtained from all individual patients included in the study.
: The authors declare the following competing financial interest(s): Patent applications on PSMA ligands with albumin-binding entities have been filed by ITM Medical Isotopes GmbH, Germany and the Paul Scherrer Institute, Switzerland. KZ, RS and CM are listed as co-inventors. The authors further declare non-financial interest(s): non-carrier-added lutetium-177 was provided by ITM Medical Isotopes GmbH, Germany.
